Los Angeles Capital Management LLC Has $77.60 Million Position in Stryker Co. (NYSE:SYK)

Los Angeles Capital Management LLC lowered its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 40.6% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 214,814 shares of the medical technology company's stock after selling 146,659 shares during the period. Los Angeles Capital Management LLC owned approximately 0.06% of Stryker worth $77,604,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Patrick M Sweeney & Associates Inc. lifted its holdings in Stryker by 1.5% in the 3rd quarter. Patrick M Sweeney & Associates Inc. now owns 2,194 shares of the medical technology company's stock worth $793,000 after buying an additional 32 shares in the last quarter. Versant Capital Management Inc lifted its stake in shares of Stryker by 4.0% in the second quarter. Versant Capital Management Inc now owns 864 shares of the medical technology company's stock worth $294,000 after acquiring an additional 33 shares in the last quarter. Stanley Laman Group Ltd. boosted its holdings in Stryker by 4.6% in the second quarter. Stanley Laman Group Ltd. now owns 752 shares of the medical technology company's stock valued at $256,000 after purchasing an additional 33 shares during the last quarter. Plimoth Trust Co. LLC grew its stake in Stryker by 0.3% during the 2nd quarter. Plimoth Trust Co. LLC now owns 9,476 shares of the medical technology company's stock valued at $3,224,000 after purchasing an additional 33 shares in the last quarter. Finally, Grimes & Company Inc. increased its holdings in Stryker by 0.4% during the 3rd quarter. Grimes & Company Inc. now owns 8,239 shares of the medical technology company's stock worth $2,977,000 after purchasing an additional 33 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on SYK. Piper Sandler reissued an "overweight" rating and set a $420.00 price target (up previously from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Needham & Company LLC raised their price objective on shares of Stryker from $393.00 to $409.00 and gave the stock a "buy" rating in a report on Wednesday, October 30th. Canaccord Genuity Group upped their target price on shares of Stryker from $360.00 to $400.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. Citigroup increased their price target on shares of Stryker from $406.00 to $411.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. Finally, Stifel Nicolaus lowered their price objective on Stryker from $375.00 to $365.00 and set a "buy" rating for the company in a report on Wednesday, July 31st. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $393.65.

Insider Transactions at Stryker

In related news, CEO Kevin Lobo sold 57,313 shares of the firm's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the transaction, the chief executive officer now owns 100,027 shares of the company's stock, valued at $36,879,954.90. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, VP M Kathryn Fink sold 2,121 shares of the firm's stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $370.00, for a total value of $784,770.00. Following the completion of the transaction, the vice president now owns 10,042 shares of the company's stock, valued at approximately $3,715,540. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Kevin Lobo sold 57,313 shares of the business's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at approximately $36,879,954.90. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 67,381 shares of company stock valued at $24,825,275. Corporate insiders own 5.90% of the company's stock.

Stryker Stock Performance

Shares of SYK stock traded up $6.13 during trading hours on Friday, reaching $375.96. The stock had a trading volume of 1,009,226 shares, compared to its average volume of 1,183,677. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The firm has a 50-day simple moving average of $361.46 and a 200-day simple moving average of $345.71. The firm has a market capitalization of $143.32 billion, a PE ratio of 40.30, a price-to-earnings-growth ratio of 2.83 and a beta of 0.91. Stryker Co. has a twelve month low of $266.93 and a twelve month high of $377.83.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. During the same period in the previous year, the firm posted $2.46 earnings per share. The business's revenue was up 11.9% on a year-over-year basis. As a group, equities analysts forecast that Stryker Co. will post 12.06 earnings per share for the current year.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.